Buprenorphine in the treatment of neuropathic pain

ACS Symposium Series

Volumn 1131, Issue , 2013, Pages 103-123

  Hans, Guy H ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC DRUGS; BUPRENORPHINE; CLINICAL EXPERIENCE; CLINICAL STUDY; CLINICAL SYNDROMES; NEUROPATHIC PAIN; PHARMACOLOGICAL PROPERTIES; TRANSDERMAL ADMINISTRATION;

HEALTH;

EID: 84905496542     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2013-1131.ch006     Document Type: Conference Paper

References (101)

1. Merskey, H. Psychological medicine, pain, and musculoskeletal disorders. Rheum. Dis. Clin. North Am. 1996, 22, 623-637.
2. McCleane, G. Pharmacological strategies in relieving neuropathic pain. Expert Opin. Pharmacother. 2004, 5, 1299-1312.
3. Arner, S.; Meyerson, B. A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988, 33, 11-23.
4. Portenoy, R. K.; Foley, K. M.; Inturrisi, C. E. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions. Pain 1990, 43, 273-286.
5. Wall, P. D. Neuropathic pain. Pain 1990, 43, 267-268.
6. Maruta, T.; Swanson, D. W.; Finlayson, R. E. Drug abuse and dependency in patients with chronic pain. Mayo Clin. Proc. 1979, 54, 241-244.
7. Porter, J.; Jick, H. Addiction rare in patients treated with narcotics. N. Engl. J. Med. 1980, 302, 123.
8. Kalman, S.; Osterberg, A.; Sorensen, J.; Boivie, J.; Bertler, A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: A study with i.V. Morphine. Eur. J. Pain 2002, 6, 69-80.
9. Rowbotham, M. C.; Twilling, L.; Davies, P. S.; Reisner, L.; Taylor, K.; Mohr, D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N. Engl. J. Med. 2003, 348, 1223-1232.
10. Jadad, A. R.; Carroll, D.; Glynn, C. J.; Moore, R. A.; McQuay, H. J. Morphine responsiveness of chronic pain: Double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992, 339, 1367-1371.
11. Hansson, P. T.; Dickenson, A. H. Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 2005, 113, 251-254.
12. Narita, M.; Imai, S.; Itou, Y.; Yajima, Y.; Suzuki, T. Possible involvement of mu1-opioid receptors in the fentanyl-or morphine-induced antinociception at supraspinal and spinal sites. Life Sci. 2002, 70, 2341-2354.
13. McCormack, K.; Prather, P.; Chapleo, C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain 1998, 78, 79-98.
14. Williams, S.; Evan, G.; Hunt, S. P. Spinal c-fos induction by sensory stimulation in neonatal rats. Neurosci. Lett. 1990, 109, 309-314.
15. Yi, D. K.; Barr, G. A. The induction of fos-like immunoreactivity by noxious thermal, mechanical and chemical stimuli in the lumbar spinal cord of infant rats. Pain 1995, 60, 257-265.
16. McLaughlin, C. R.; Dewey, W. L. A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests. Pharmacol. Biochem. Behav. 1994, 49, 1017-1023.
17. Guirimand, F.; Chauvin, M.; Willer, J. C.; Le Bars, D. Buprenorphine blocks diffuse noxious inhibitory controls in the rat. Eur. J. Pharmacol. 1995, 294, 651-659.
18. Le Bars, D.; Dickenson, A. H.; Besson, J. M. Diffuse noxious inhibitory controls (dnic). Ii. Lack of effect on non-convergent neurones, supraspinal involvement and theoretical implications. Pain 1979, 6, 305-327.
19. Le Bars, D.; Dickenson, A. H.; Besson, J. M. Diffuse noxious inhibitory controls (dnic). I. Effects on dorsal horn convergent neurones in the rat. Pain 1979, 6, 283-304.
20. Morton, C. R.; Maisch, B.; Zimmermann, M. Diffuse noxious inhibitory controls of lumbar spinal neurons involve a supraspinal loop in the cat. Brain Res. 1987, 410, 347-352.
21. Kakigi, R. Diffuse noxious inhibitory control. Reappraisal by pain-related somatosensory evoked potentials following co2 laser stimulation. J. Neurol. Sci. 1994, 125, 198-205.
22. Dickenson, A. H.; Le Bars, D.; Besson, J. M. Diffuse noxious inhibitory controls (dnic). Effects on trigeminal nucleus caudalis neurones in the rat. Brain Res. 1980, 200, 293-305.
23. Dickenson, A. H.; Rivot, J. P.; Chaouch, A.; Besson, J. M.; Le Bars, D. Diffuse noxious inhibitory controls (dnic) in the rat with or without pcpa pretreatment. Brain Res. 1981, 216, 313-321.
24. Le Bars, D.; Chitour, D.; Kraus, E.; Dickenson, A. H.; Besson, J. M. Effect of naloxone upon diffuse noxious inhibitory controls (dnic) in the rat. Brain Res. 1981, 204, 387-402.
25. Le Bars, D.; Chitour, D.; Kraus, E.; Clot, A. M.; Dickenson, A. H.; Besson, J. M. The effect of systemic morphine upon diffuse noxious inhibitory controls (dnic) in the rat: Evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones. Brain Res. 1981, 215, 257-274.
26. Ciruela, A.; Dixon, A. K.; Bramwell, S.; Gonzalez, M. I.; Pinnock, R. D.; Lee, K. Identification of mek1 as a novel target for the treatment of neuropathic pain. Br. J. Pharmacol. 2003, 138, 751-756.
27. Jin, S. X.; Zhuang, Z. Y.; Woolf, C. J.; Ji, R. R. P38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci. 2003, 23, 4017-4022.
28. Rausch, O.; Newton, R. A.; Bingham, S.; Macdonald, R.; Case, C. P.; Sanger, G. J.; Lawson, S. N.; Reith, A. D. Nerve injury-associated kinase: A sterile 20-like protein kinase up-regulated in dorsal root ganglia in a rat model of neuropathic pain. Neuroscience 2000, 101, 767-777.
29. Milligan, E. D.; Twining, C.; Chacur, M.; Biedenkapp, J.; OConnor, K.; Poole, S.; Tracey, K.; Martin, D.; Maier, S. F.; Watkins, L. R. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. 2003, 23, 1026-1040.
30. Pick, C. G.; Peter, Y.; Schreiber, S.; Weizman, R. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res. 1997, 744, 41-46.
31. Schreiber, S.; Backer, M. M.; Yanai, J.; Pick, C. G. The antinociceptive effect of fluvoxamine. Eur. Neuropsychopharmacol. 1996, 6, 281-284.
32. Womer, D. E.; DeLapp, N. W.; Shannon, H. E. Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain 1997, 70, 223-228.
33. Wheeler-Aceto, H.; Cowan, A. Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur. J. Pharmacol. 1991, 195, 411-413.
34. Lutfy, K.; Eitan, S.; Bryant, C. D.; Yang, Y. C.; Saliminejad, N.; Walwyn, W.; Kieffer, B. L.; Takeshima, H.; Carroll, F. I.; Maidment, N. T.; Evans, C. J. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J. Neurosci. 2003, 23, 10331-10337.
35. McLaughlin, C. R.; Tao, Q.; Abood, M. E. Analysis of the antinociceptive actions of the kappa-opioid agonist enadoline (ci-977) in neonatal and adult rats: Comparison to kappa-opioid receptor mrna ontogeny. Drug Alcohol Depend. 1995, 38, 261-269.
36. North, R. A. Twelfth gaddum memorial lecture. Drug receptors and the inhibition of nerve cells. Br. J. Pharmacol. 1989, 98, 13-28.
37. Sanchez, J. A.; Gonoi, T.; Inagaki, N.; Katada, T.; Seino, S. Modulation of reconstituted atp-sensitive k(+)-channels by gtp-binding proteins in a mammalian cell line. J. Physiol. 1998, 507 (Pt 2), 315-324.
38. Wada, Y.; Yamashita, T.; Imai, K.; Miura, R.; Takao, K.; Nishi, M.; Takeshima, H.; Asano, T.; Morishita, R.; Nishizawa, K.; Kokubun, S.; Nukada, T. A region of the sulfonylurea receptor critical for a modulation of atp-sensitive k(+) channels by g-protein betagamma-subunits. EMBO J. 2000, 19, 4915-4925.
39. Mark, M. D.; Herlitze, S. G-protein mediated gating of inward-rectifier k+ channels. Eur. J. Biochem. 2000, 267, 5830-5836.
40. Scott, D. H.; Arthur, G. R.; Scott, D. B. Haemodynamic changes following buprenorphine and morphine. Anaesthesia 1980, 35, 957-961.
41. Ocana, M.; Del Pozo, E.; Barrios, M.; Baeyens, J. M. Subgroups among mu-opioid receptor agonists distinguished by atp-sensitive k+ channel-acting drugs. Br. J. Pharmacol. 1995, 114, 1296-1302.
42. Yang, E. K.; Takimoto, K.; Hayashi, Y.; de Groat, W. C.; Yoshimura, N. Altered expression of potassium channel subunit mrna and alpha-dendrotoxin sensitivity of potassium currents in rat dorsal root ganglion neurons after axotomy. Neuroscience 2004, 123, 867-874.
43. Wood, J. N.; Abrahamsen, B.; Baker, M. D.; Boorman, J. D.; Donier, E.; Drew, L. J.; Nassar, M. A.; Okuse, K.; Seereeram, A.; Stirling, C. L.; Zhao, J. Ion channel activities implicated in pathological pain. Novartis Found. Symp. 2004, 261, 32-40, discussion 40-54.
44. Wnendt, S.; Kruger, T.; Janocha, E.; Hildebrandt, D.; Englberger, W. Agonistic effect of buprenorphine in a nociceptin/ofq receptor-triggered reporter gene assay. Mol. Pharmacol. 1999, 56, 334-338.
45. Bloms-Funke, P.; Gillen, C.; Schuettler, A. J.; Wnendt, S. Agonistic effects of the opioid buprenorphine on the nociceptin/ofq receptor. Peptides 2000, 21, 1141-1146.
46. Hawkinson, J. E.; Acosta-Burruel, M.; Espitia, S. A. Opioid activity profiles indicate similarities between the nociceptin/orphanin fq and opioid receptors. Eur. J. Pharmacol. 2000, 389, 107-114.
47. Huang, P.; Kehner, G. B.; Cowan, A.; Liu-Chen, L. Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 2001, 297, 688-695.
48. Lundborg, C. N.; Nitescu, P. V.; Appelgren, L. K.; Curelaru, I. D. Progressive systemic sclerosis: Intrathecal pain management. Reg. Anesth. Pain Med. 1999, 24, 89-93.
49. Tejwani, G. A.; Rattan, A. K. The role of spinal opioid receptors in antinociceptive effects produced by intrathecal administration of hydromorphone and buprenorphine in the rat. Anesth. Analg. 2002, 94, 1542-1546, table of contents.
50. Hentz, J. G.; Valle-Robillart, A.; Franckhauser, J.; Froehly, S.; Dupeyron, J. P. The use of intrathecal morphine in thoracic anesthesia. J. Cardiothorac. Anesth. 1989, 3, 24.
51. Nitescu, P.; Dahm, P.; Appelgren, L.; Curelaru, I. Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of "refractory" nonmalignant pain. Clin. J. Pain 1998, 14, 17-28.
52. Guirimand, F.; Chauvin, M.; Willer, J. C.; Le Bars, D. Effects of intrathecal and intracerebroventricular buprenorphine on a c-fiber reflex in the rat. J. Pharmacol. Exp. Ther. 1995, 275, 629-637.
53. Inagaki, Y.; Mashimo, T.; Yoshiya, I. Mode and site of analgesic action of epidural buprenorphine in humans. Anesth. Analg. 1996, 83, 530-536.
54. Wang, J. J.; Ho, S. T.; Hu, O. Y.; Chu, K. M. An innovative cold tail-flick test: The cold ethanol tail-flick test. Anesth. Analg. 1995, 80, 102-107.
55. Kouya, P. F.; Hao, J. X.; Xu, X. J. Buprenorphine alleviates neuropathic painlike behaviors in rats after spinal cord and peripheral nerve injury. Eur. J. Pharmacol. 2002, 450, 49-53.
56. Xu, X. J.; Hao, J. X.; Aldskogius, H.; Seiger, A.; Wiesenfeld-Hallin, Z. Chronic pain-related syndrome in rats after ischemic spinal cord lesion: A possible animal model for pain in patients with spinal cord injury. Pain 1992, 48, 279-290.
57. Yu, W.; Hao, J. X.; Xu, X. J.; Wiesenfeld-Hallin, Z. Comparison of the anti-allodynic and antinociceptive effects of systemic; intrathecal and intracerebroventricular morphine in a rat model of central neuropathic pain. Eur. J. Pain 1997, 1, 17-29.
58. Kupers, R.; Yu, W.; Persson, J. K.; Xu, X. J.; Wiesenfeld-Hallin, Z. Photochemically-induced ischemia of the rat sciatic nerve produces a dose-dependent and highly reproducible mechanical, heat and cold allodynia, and signs of spontaneous pain. Pain 1998, 76, 45-59.
59. Bulka, A.; Plesan, A.; Xu, X. J.; Wiesenfeld-Hallin, Z. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 2002, 95, 103-109.
60. Christoph, T.; Kogel, B.; Schiene, K.; Meen, M.; De Vry, J.; Friderichs, E. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur. J. Pharmacol. 2005, 507, 87-98.
61. Tyers, M. B. A classification of opiate receptors that mediate antinociception in animals. Br. J. Pharmacol. 1980, 69, 503-512.
62. Canta, A.; Chiorazzi, A.; Meregalli, C.; Carozzi, V.; Oggioni, N.; Lauria, G.; Lombardi, R.; Bianchi, R.; Porretta-Serapiglia, C.; Cavaletti, G. Continuous buprenorphine delivery effect in streptozotocine-induced painful diabetic neuropathy in rats. J. Pain 2009, 10, 961-968.
63. Koppert, W.; Dern, S. K.; Sittl, R.; Albrecht, S.; Schuttler, J.; Schmelz, M. A new model of electrically evoked pain and hyperalgesia in human skin: The effects of intravenous alfentanil, s(+)-ketamine, and lidocaine. Anesthesiology 2001, 95, 395-402.
64. Induru, R. R.; Davis, M. P. Buprenorphine for neuropathic pain-targeting hyperalgesia. Am. J. Hospice Palliative Care 2009, 26, 470-473.
65. Zenz, M.; Strumpf, M.; Tryba, M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J. Pain Symptom Manage. 1992, 7, 69-77.
66. Omote, K.; Ohmori, H.; Kawamata, M.; Matsumoto, M.; Namiki, A. Intrathecal buprenorphine in the treatment of phantom limb pain. Anesth. Analg. 1995, 80, 1030-1032.
67. Rudy, T. A.; Yaksh, T. L. Hyperthermic effects of morphine: Set point manipulation by a direct spinal action. Br. J. Pharmacol. 1977, 61, 91-96.
68. Kavee, E. H.; Bernstein, J.; Zakowski, M. I.; Ramanathan, S. The hypothermic action of epidural and subarachnoid morphine in parturients. Reg. Anesth. 1991, 16, 325-328.
69. Sevarino, F. B.; Johnson, M. D.; Lema, M. J.; Datta, S.; Ostheimer, G. W.; Naulty, J. S. The effect of epidural sufentanil on shivering and body temperature in the parturient. Anesth. Analg. 1989, 68, 530-533.
70. Glynn, C. J.; Jamous, M. A.; Teddy, P. J.; Moore, R. A.; Lloyd, J. W. Role of spinal noradrenergic system in transmission of pain in patients with spinal cord injury. Lancet 1986, 2, 1249-1250.
71. Glynn, C. J.; Jamous, M. A.; Teddy, P. J. Cerebrospinal fluid kinetics of epidural clonidine in man. Pain 1992, 49, 361-367.
72. Gotoda, Y.; Kambara, N.; Sakai, T.; Kishi, Y.; Kodama, K.; Koyama, T. The morbidity, time course and predictive factors for persistent post-thoracotomy pain. Eur. J. Pain 2001, 5, 89-96.
73. Perttunen, K.; Tasmuth, T.; Kalso, E. Chronic pain after thoracic surgery: A follow-up study. Acta Anaesthesiol. Scand. 1999, 43, 563-567.
74. Benedetti, F.; Vighetti, S.; Amanzio, M.; Casadio, C.; Oliaro, A.; Bergamasco, B.; Maggi, G. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998, 74, 205-211.
75. Likar, R.; Griessinger, N.; Sadjak, A.; Sittl, R. transdermal buprenorphine for treatment of chronic tumor and non-tumor pain. Wien. Med. Wochenschr. 2003, 153, 317-322.
76. Penza, P.; Campanella, A.; Martini, A.; Melli, G.; Lombardi, R.; Camozzi, F.; Devigili, G.; Lauria, G. Short-and intermediate-term efficacy of buprenorphine tds in chronic painful neuropathies. J. Peripher. Nerv. Syst. 2008, 13, 283-288.
77. Guetti, C.; Angeletti, C.; Marinangeli, F.; Ciccozzi, A.; Baldascino, G.; Paladini, A.; Varrassi, G. Transdermal buprenorphine for central neuropathic pain: Clinical reports. Pain Practice 2011, 11, 446-452.
78. Przeklasa-Muszynska, A.; Dobrogowski, J. Transdermal buprenorphine in the treatment of cancer and non-cancer pain -The results of multicenter studies in poland. Pharmacol. Rep. 2011, 63, 935-948.
79. Przeklasa-Muszynska, A.; Dobrogowski, J. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: Results from a large multicenter, non-interventional post-marketing study in poland. Curr. Med. Res. Opin. 2011, 27, 1109-1117.
80. Pergolizzi, J.; Aloisi, A. M.; Dahan, A.; Filitz, J.; Langford, R.; Likar, R.; Mercadante, S.; Morlion, B.; Raffa, R. B.; Sabatowski, R.; Sacerdote, P.; Torres, L. M.; Weinbroum, A. A. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Practice 2010, 10, 428-450.
81. Davis, M. P. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J. Supportive Oncol. 2012.
82. Kobayashi, T.; Ikeda, K.; Togashi, S.; Itoh, N.; Kumanishi, T. Effects of sigma ligands on the nociceptin/orphanin fq receptor co-expressed with the g-protein-activated k+ channel in xenopus oocytes. Br. J. Pharmacol. 1997, 120, 986-987.
83. Lambert, D. G. The nociceptin/orphanin fq receptor: A target with broad therapeutic potential. Nat. Rev. Drug Discovery 2008, 7, 694-710.
84. Caldwell, J. P.; Matasi, J. J.; Fernandez, X.; McLeod, R. L.; Zhang, H.; Fawzi, A.; Tulshian, D. B. Synthesis and structure-activity relationships of n-substituted spiropiperidines as nociceptin receptor ligands: Part 2. Bioorg. Med. Chem. Lett. 2009, 19, 1164-1167.
85. Huang, X. Q.; Jiang, H. L.; Luo, X. M.; Chen, K. X.; Zhu, Y. C.; Ji, R. Y.; Cao, Y. Study on mechanism of interaction of nociceptin and opioids binding with opioid receptor-like 1 receptor. Acta Pharmacol. Sin. 2000, 21, 536-546.
86. Mustazza, C.; Bastanzio, G. Development of nociceptin receptor (nop) agonists and antagonists. Med. Res. Rev. 2011, 31, 605-648.
87. Mustazza, C.; Borioni, A.; Sestili, I.; Sbraccia, M.; Rodomonte, A.; Del Giudice, M. R. Synthesis and pharmacological evaluation of 1,2- dihydrospiro[isoquinoline-4(3h),4′-piperidin]-3-ones as nociceptin receptor agonists. J. Med. Chem. 2008, 51, 1058-1062.
88. Chen, X.; Geller, E. B.; Adler, M. W. Nociceptin/orphanin fq blocks the antinociception induced by mu, kappa and delta opioid agonists on the cold water tail-flick test. Eur. J. Pharmacol. 2007, 557, 32-36.
89. Gunduz, O.; Sipos, F.; Spagnolo, B.; Kocsis, L.; Magyar, A.; Orosz, G.; Borsodi, A.; Calo, G.; Benyhe, S. In vitro binding and functional studies of ac-ryyrik-ol and its derivatives, novel partial agonists of the nociceptin/orphanin f/q receptor. Neurosignals 2006, 15, 91-101.
90. Chang, M.; Peng, Y. L.; Dong, S. L.; Han, R. W.; Li, W.; Yang, D. J.; Chen, Q.; Wang, R. Structure-activity studies on different modifications of nociceptin/orphanin fq: Identification of highly potent agonists and antagonists of its receptor. Regul. Pept. 2005, 130, 116-122.
91. Kapusta, D. R.; Burmeister, M. A.; Calo, G.; Guerrini, R.; Gottlieb, H. B.; Kenigs, V. A. Functional selectivity of nociceptin/orphanin fq peptide receptor partial agonists on cardiovascular and renal function. J. Pharmacol. Exp. Ther. 2005, 314, 643-651.
92. Rover, S.; Adam, G.; Cesura, A. M.; Galley, G.; Jenck, F.; Monsma, F. J., Jr.; Wichmann, J.; Dautzenberg, F. M. High-affinity, non-peptide agonists for the orl1 (orphanin fq/nociceptin) receptor. J. Med. Chem. 2000, 43, 1329-1338.
93. Khroyan, T. V.; Polgar, W. E.; Orduna, J.; Montenegro, J.; Jiang, F.; Zaveri, N. T.; Toll, L. Differential effects of nociceptin/orphanin fq (nop) receptor agonists in acute versus chronic pain: Studies with bifunctional nop/mu receptor agonists in the sciatic nerve ligation chronic pain model in mice. J. Pharmacol. Exp. Ther. 2011, 339, 687-693.
94. Del Giudice, M. R.; Borioni, A.; Bastanzio, G.; Sbraccia, M.; Mustazza, C.; Sestili, I. Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor. Eur. J. Med. Chem. 2011, 46, 1207-1221.
95. Sestili, I.; Borioni, A.; Mustazza, C.; Rodomonte, A.; Turchetto, L.; Sbraccia, M.; Riitano, D.; Del Giudice, M. R. A new synthetic approach of n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide (jtc-801) and its analogues and their pharmacological evaluation as nociceptin receptor (nop) antagonists. Eur. J. Med. Chem. 2004, 39, 1047-1057.
96. Redrobe, J. P.; Calo, G.; Regoli, D.; Quirion, R. Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn-Schmiedebergs Arch. Pharmacol. 2002, 365, 164-167.
97. Shinkai, H.; Ito, T.; Iida, T.; Kitao, Y.; Yamada, H.; Uchida, I. 4-aminoquinolines: Novel nociceptin antagonists with analgesic activity. J. Med. Chem. 2000, 43, 4667-4677.
98. http://clinicaltrials.gov/ct2/results?term=GRT+6005&Search=Search
99. http://clinicaltrialsfeeds.org/clinical-trials/results/term=Drug+GRT6005
100. Forest Laboratories press release. http://investor.frx.com/press-release/ rd-news/forest-laboratories-and-gruenenthal-enter-licensing- agreementdevelopment-and
101. Kimmel, H. L.; Tallarida, R. J.; Holtzman, S. G. Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat. Psychopharmacology 1997, 133, 372-377.